Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value

Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +12.5%

FINANCIAL BRIEF: For the six months ended 30 June 2014, Cyprotex plc revenues increased 19% to L5.4M. Net loss totaled L405K vs. income of L298K. Revenues reflect North America segment increase of 50% to L2.9M, United Kingdom segment increase of 4% to L956K. Net loss reflects Administrative costs increase of 44% to L4.8M (expense), Finance cost increase from L47K to L236K (expense). more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score  

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

Recent History
Latest interim period (ended 30th Jun '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: N/A Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Cyprotex
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
N+1 Singer Jens Lindqvist Sheena Berry ,

Profile Summary

Cyprotex PLC (Cyprotex) is a United Kingdom-based holding company. The Company is engaged in providing in vitro and in silico ADMET and PK (Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics) information to various industries including the pharmaceutical, biotechnology, cosmetic, personal care, agrochemical, chemical industries and academia. The Company’s trading subsidiaries are Cyprotex Discovery Limited and Cyprotex US, LLC (formerly Apredica LLC. Cyprotex provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical.

Directors: Anthony Baxter (CEO) 54, John Dootson (CFO) 52, Mark Warburton (SEC) 60, Ian Johnson (NEC) 60, Ralph Harris (NED) 71, Christopher Mills (NED) 62,

No. of Employees: 83 No. of Shareholders: 0

Last Annual December 31st, 2013
Last Interim June 30th, 2014
Shares in Issue 22,442,699
Free Float 12.9m (57.6%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Intl-aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

CRX Share Price Performance CRX Quote
0.0  0.0%
Traded 11:42am · Minimum 15 min delayed · NMS: 3.00k

Latest CRX News Announcements (delayed)

Upcoming CRX Events
Friday 24th July, 2015 (estimate)
Cyprotex PLC Annual Shareholders Meeting

Recent ↓
Monday 28th July, 2014
Cyprotex PLC Reverse Split For CRX.L
Thursday 24th July, 2014
Cyprotex PLC Annual Shareholders Meeting
Tuesday 25th March, 2014
Preliminary 2013 Cyprotex PLC Earnings Release
Thursday 23rd January, 2014
Cyprotex PLC Trading Update
Thursday 26th September, 2013
Cyprotex PLC General Meeting
Wednesday 21st August, 2013
Cyprotex PLC Convertible Offering Filing
Wednesday 7th August, 2013
Interim 2013 Cyprotex PLC Earnings Release
Tuesday 16th July, 2013
Cyprotex PLC Annual General Meeting
Thursday 20th June, 2013
Cyprotex PLC H1 2013 Trading Update
Thursday 21st March, 2013
Preliminary 2012 Cyprotex PLC Earnings Release

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy CRX

Access CRX Analytics Now!